We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
Burford Capital
BUR
$984M
| $1.84M | ﹤0.01% |
450,000
| – | – |
|
877
VICI Properties
VICI
$27.8B
| $1.83M | ﹤0.01% |
69,000
-463,500
| -87% | -$13M |
|
878
Insulet
PODD
$9.57B
| $1.78M | ﹤0.01% |
+11,700
| New | +$1.95M |
|
|
NSA
879
DELISTED
National Storage Affiliates Trust
NSA
| $1.78M | ﹤0.01% |
40,000
-160,000
| -80% | -$6.86M |
|
880
Sable Offshore Corp
SOC
$944M
| $1.74M | ﹤0.01% |
+564,412
| New | +$7.18M |
|
|
AARD
881
Aardvark Therapeutics
AARD
$108M
| $1.73M | ﹤0.01% |
300,000
| – | – |
|
882
Rollins
ROL
$16.6B
| $1.66M | ﹤0.01% |
39,750
-171,266
| -81% | -$8.75M |
|
883
Establishment Labs
ESTA
$2.22B
| $1.55M | ﹤0.01% |
+18,079
| New | +$1.3M |
|
884
Booz Allen Hamilton
BAH
$8.68B
| $1.53M | ﹤0.01% |
25,148
-205,052
| -89% | -$15.7M |
|
885
C4 Therapeutics
CCCC
$423M
| $1.52M | ﹤0.01% |
+325,000
| New | +$1.11M |
|
|
HACQ
886
HCM IV Acquisition Corp
HACQ
$377M
| $1.5M | ﹤0.01% |
+150,000
| New | +$1.49M |
|
887
Four Corners Property Trust
FCPT
$2.69B
| $1.47M | ﹤0.01% |
60,000
-690,000
| -92% | -$17.2M |
|
888
KLX Energy Services
KLXE
$33.1M
| $1.42M | ﹤0.01% |
550,000
+450,000
| +450% | +$1.34M |
|
|
RNA
889
Atrium Therapeutics
RNA
$180M
| $1.34M | ﹤0.01% |
100,000
-83,580
| -46% | -$1.09M |
|
890
ResMed
RMD
$31.7B
| $1.33M | ﹤0.01% |
+6,803
| New | +$1.41M |
|
|
DMRA
891
Damora Therapeutics
DMRA
$1.62B
| $1.26M | ﹤0.01% |
+48,426
| New | +$1.17M |
|
|
MSLE
892
Satellos Bioscience
MSLE
$213M
| $1.17M | ﹤0.01% |
150,000
-230,354
| -61% | -$1.58M |
|
893
Pasithea Therapeutics
KTTA
$19M
| $1.08M | ﹤0.01% |
2,100,000
| – | – |
|
894
Xilio Therapeutics
XLO
$59M
| $1.07M | ﹤0.01% |
+111,541
| New | +$932K |
|
895
AdaptHealth
AHCO
$760M
| $1.04M | ﹤0.01% |
+100,000
| New | +$1.12M |
|
|
ADGM
896
Adagio Medical Holdings
ADGM
$13.4M
| $820K | ﹤0.01% |
1,258,501
| – | – |
|
897
Smart Sand
SND
$229M
| $752K | ﹤0.01% |
+150,000
| New | +$754K |
|
898
Douglas Emmett
DEI
$1.81B
| $751K | ﹤0.01% |
+63,653
| New | +$716K |
|
|
GCGRW
899
General Catalyst Global Resilience Merger Corp Warrants
GCGRW
$7.04M
| $711K | ﹤0.01% |
+725,000
| New | +$659K |
|
900
Cigna
CI
$73.5B
| $646K | ﹤0.01% |
2,343
-343,328
| -99% | -$97M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.